compounded semaglutide fda warning november 2025 issued 25 letters to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Novo Nordisk expands legal action

Final Thoughts Aetna does not typically cover Ozempic for weight loss because it is not FDA-approved for obesity

While the physiological relevance of irisin in humans is under investigation, growing preclinical evidence suggests its role in lipid metabolism, browning of white adipose tissue, and glucose uptake

as BMI increases above 25, average annual health care spending among Medicare beneficiaries increases

Cell 81 , 801809 (1995)

A.DincerF.ThakkarB.Sahin-EfeA.et al

Obesity's next phase won't be won by whoever takes off the most weight it'll be won by whoever shows the cleanest risk-benefit across a widening set of conditions